Pacific Edge Limited (ASX:PEB)

Australia flag Australia · Delayed Price · Currency is AUD
0.1350
+0.0300 (28.57%)
Aug 25, 2025, 12:48 PM AEST
28.57%
Market Cap122.76M
Revenue (ttm)20.67M
Net Income (ttm)-27.20M
Shares Outn/a
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume204,795
Average Volume9,803
Open0.1200
Previous Close0.1050
Day's Range0.1200 - 0.1450
52-Week Range0.0500 - 0.1800
Beta0.50
RSI67.20
Earnings DateMay 23, 2025

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva... [Read more]

Sector Healthcare
Founded 2001
Employees 114
Stock Exchange Australian Securities Exchange
Ticker Symbol PEB
Full Company Profile

Financial Performance

In 2024, Pacific Edge's revenue was 22.75 million, a decrease of -9.83% compared to the previous year's 25.23 million. Losses were -29.94 million, 1.36% more than in 2023.

Financial numbers in NZD Financial Statements

News

Half Year 2025 Pacific Edge Ltd Earnings Call Transcript

Half Year 2025 Pacific Edge Ltd Earnings Call Transcript

9 months ago - GuruFocus